A Agilent Technologies Inc.

Dow R. Wilson to Join Agilent’s Board of Directors

Agilent Technologies, Inc. (NYSE: A) today announced that Dow R. Wilson, CEO of Varian Medical Systems, Inc., has been elected to its board of directors, effective March 20, 2018.

Since 2012 Wilson has been CEO of Varian Medical, a Palo Alto, Calif-based medical device and software products company for treating cancer. Prior to his appointment as CEO, Wilson was chief operating officer and executive vice president, and before that he was president of Varian Medical’s Oncology Systems business.

Wilson also had a 19-year career with GE Healthcare, culminating in his position as CEO of GE’s Healthcare Information Technology unit.

“Dow brings an important breadth of experience in the healthcare industry. He is a well-respected leader, who is skilled at identifying new opportunities, and building new businesses,” said Mike McMullen, Agilent’s president and CEO. “His insights about healthcare trends worldwide will be particularly valuable as Agilent continues to expand in this field globally.”

“I am very pleased to welcome Dow to the Agilent board,” said Koh Boon Hwee, Agilent chairman. “He adds an important and well-informed perspective about the medical technology needs of customers and about emerging markets. I look forward to working with him.”

Wilson is also a member of the Board of Directors of AdvaMed, a U.S. trade association representing 80 percent of the medical technology firms in the U.S., and Varex Imaging Corporation, which was created through the successful spin-off of Varian Medical. His term on the Varex board naturally ends in February 2018. Formerly, Wilson was lead independent director of Saba Software, Inc.

In 2014, he was appointed by then-U.S. Secretary of Commerce, Penny Pritzker, to the newly formed President’s Advisory Council on Doing Business in Africa.

Wilson received an MBA from the Tuck School of Business at Dartmouth College, New Hampshire and a Bachelor of Arts degree from Brigham Young University, Utah.

“I have long admired Agilent’s scientific solutions, as well as its strong customer focus and impeccable reputation for integrity. I am very pleased to be joining Agilent’s board at this exciting time as the company continues its expansion into medical healthcare,” Wilson said.

About Agilent

Agilent Technologies, Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, working with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.5 billion in fiscal 2017 and employs about 13,500 people worldwide. Information about Agilent is available at www.agilent.com.

EN
18/01/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Key facts and statistics - fiscal 2025

A summary company profile, detailing Agilent Technologies, Inc.’s business operations and financial highlights.

Agilent Technologies, Inc. - October 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch